banner
JNK-c-Jun inhibitor CC-401 hydrochloride, Purity ≥98%
Inquiry

Cat. No.: X23-10-ZQ931

JNK-c-Jun inhibitor CC-401 hydrochloride, Purity ≥98%

Synonym: CC-401 hydrochloride; 1438391-30-0; CC-401 (hydrochloride); CC-401 HCl; CC401 HCl; 3-(3-(2-(Piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole hydrochloride; 3-[3-(2-Piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; JNK-c-Jun inhibitor

  • MDL: MFCD21364765
  • CAS Number: 1438391-30-0
  • Compound CID: 66576998
img
Product Size
10 mg; 25 mg; 50 mg; 100 mg
Price
Datasheet
MSDS
Properties
Description
CC-401 hydrochloride, soluble in DMSO, water and ethanol, is an inhibitor of c-jun N-terminal kinase (JNK) signaling.
Molecular Weight
424.93
Molecular Formula
C22H25ClN6O
Form
Lyophilized powder
Purity
≥98%
Solubility
DMSO: 73 mg/mL (171.79 mM); Water: 73 mg/mL (171.79 mM); Ethanol: 2 mg/mL (4.7 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
CC-401 hydrochloride is employed in research targeting JNK inhibition for the treatment of fibrosis and oncological disorders.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0